Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Baxter
Harvard Business School
Johnson and Johnson
AstraZeneca

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LCL161

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug LCL161?

LCL161 is an investigational drug.

There have been 10 clinical trials for LCL161. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Lung Neoplasms, and Multiple Myeloma. The leading clinical trial sponsors are Novartis Pharmaceuticals, SCRI Development Innovations, LLC, and M.D. Anderson Cancer Center.

There are twenty-one US patents protecting this investigational drug and three hundred and twenty-nine international patents.

Recent Clinical Trials for LCL161
TitleSponsorPhase
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaNovartis PharmaceuticalsPhase 1
A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatNovartis PharmaceuticalsPhase 1
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesNovartis PharmaceuticalsPhase 1/Phase 2

See all LCL161 clinical trials

Clinical Trial Summary for LCL161

Top disease conditions for LCL161
Top clinical trial sponsors for LCL161

See all LCL161 clinical trials

US Patents for LCL161

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LCL161   Start Trial Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein Novartis AG (Basel, CH)   Start Trial
LCL161   Start Trial Anti-CDH6 antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
LCL161   Start Trial NOL3 is a predictor of patient outcome Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
LCL161   Start Trial Combination of IAP inhibitors and FLT3 inhibitors Novartis AG (Basel, CH)   Start Trial
LCL161   Start Trial SMAC peptidometics useful as IAP inhibitors Novartis AG (Basel, CH)   Start Trial
LCL161   Start Trial (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrro- lidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LCL161

Drugname Country Document Number Estimated Expiration Related US Patent
LCL161 Argentina 077869 2029-08-12   Start Trial
LCL161 Australia 2010283748 2029-08-12   Start Trial
LCL161 Australia 2014213533 2029-08-12   Start Trial
LCL161 Australia 2016203145 2029-08-12   Start Trial
LCL161 Australia 2017254950 2029-08-12   Start Trial
LCL161 Brazil 112012003118 2029-08-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKinsey
McKesson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.